AR and prostate carcinoma: The driving role of AR signaling in early and late prostate cancer spurred the development and approval of drugs addressing specific steps of this pathway, including gonadotropin-releasing hormone (GnRH) analogues that centrally suppress androgen synthesis, the cytochrome P450 17A1 (CYP17A) inhibitor abiraterone acetate, which locally inhibits androgen synthesis in the testis, prostate and adrenal glands, and competitive antagonists, including enzalutamide, apalutamide and darolutamide, which inhibit AR function [15,16,17,18,19].